ClinicalTrials.gg
Active, not recruitingNCT06672055Updated Oct 9, 2026

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

A Phase 2 interventional study of VXA-CoV2-3.1 and COMIRNATY® in SARS-CoV2 and COVID-19, sponsored by Vaxart. Active, not recruiting at 145 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Vaxart · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5,485
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
57th of 1,321
5,485 · median 91
Started
2024
with 73 others
Phase 2
349 of 1,859
14 open now
Primary completion
2027-05
later than 126 of 208 live
Registered
1,769th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 57th largest by planned enrollment of the 1,321 interventional ones that give a count, is one of 74 that started in 2024, is one of 349 in phase 2, reaches primary completion later than 126 of the 208 other live ones, and was the 1,769th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).

In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.

03

Conditions studied

  • SARS-CoV2
  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 18 years of age and above, at time of screening.
  2. Completed primary approved/authorized COVID-19 vaccination series and have received ≥ 2 mRNA vaccine doses.
  3. Last COVID-19 vaccine received ≥6 months prior to study vaccination.
  4. Male and female participants of must agree to consistently use a highly effective method of from at least 30 days prior to enrollment and through 3 months after the last study vaccination.
  5. Male participants must refrain from sperm donation from the day of study vaccination through the end of the study. Female participants must refrain from egg donation at least 30 days prior to study vaccination through the end of the study.
  6. Is medically stable, as determined by the site investigator (based on review of health status, vital signs, medical history, and physical examination) with screening lab values within normal limits or abnormalities assessed as not . Screening count must be >140,000/μL.
  7. Agree to not participate in any other SARS-CoV-2 infection prevention trials (vaccine, drug, biologic, PReP) during participation in the study.
  8. Willing and able to provide prior to initiation of study procedures.
  9. Available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study.
  10. Negative rapid antigen Covid test at the screening visit and on Day 1 prior to vaccine dosing. An indeterminate should be considered as positive for the purposes of screen-failing participants.

Exclusion criteria

Exclusion Criteria:

  1. Participant has an acute illness as defined by any of the following (note: assessment may be repeated once during screening period) as determined by the site investigator, within 72 hours prior to vaccination:

    1. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol.
    2. Presence of a fever ≥ 38.0°C (100.4°F) measured orally at baseline, on Day 1 prior to vaccination.
    3. Receipt of antipyretic/analgesic medications within 24 hours prior to vaccine administration.
  2. Participant has had a positive COVID test within 90 days prior to screening.
  3. Current or planned participation in any other interventional clinical trial.
  4. Participation in research involving any product within 45 days prior to study vaccination.
  5. Receipt of any approved or authorized products intended to prevent SARS-CoV2 infection within 6 months prior to study vaccination.
  6. Receipt or donation of blood products or immunoglobulins within 60 days prior to enrollment or planned administration during the study.
  7. Received influenza vaccination within 14 days prior to study vaccination, or any other vaccine within 30 days prior to study vaccination.
  8. Any or immunodeficiency disease/condition (including and not limited to untreated or advanced infection with \<200 cells/mm\^3, history of AIDS defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV, severe combined immunodeficiency (SCID), hypogammaglobulinemia, asplenia or functional asplenia). Gout managed only for elevated uric acid without gout flares would not be exclusionary, provided no prohibited medications were used.
  9. Unstable medical or psychiatric illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to enrollment. Note: diabetes mellitus (Types 1 \& 2) are not excluded if assessed by the principal investigator (PI) as well-controlled.
  10. Administration of , systemic , or other immune-modifying drugs within the following timeframes:

    1. B-cell therapies within the 6 months prior to first study vaccination
    2. Prednisone, ≥20 mg for more than 2 weeks, within the 30 days prior to study vaccination
    3. Other medications in this category, including but not limited to high-dose inhaled corticosteroids (>800 mcg/day of beclomethasone dipropionate or equivalent); antimetabolites; transplant immunosuppressive agents; alkylating agents; cell-depleting agents; or cancer chemotherapeutics, within the 90 days prior to study vaccination.
    4. Any medication for any period of time that, in the opinion of the site investigator, could impede immune response to vaccination.
    5. Use of any dose montelukast OR inhaled, intranasal, intra-articular, or systemic corticosteroids within 2 weeks prior to study vaccination.
    6. Planned use of any of the above medications during the study.
    7. Concomitant allergen immunotherapy (AIT) will be allowed only if the participant is stable in the maintenance phase of AIT. Maintenance AIT should not be dosed for at least 7 days before and 7 days after study vaccine dosing, and the PI must document the treating allergist's approval.
  11. Known to IM injection or blood draws (e.g. bleeding diathesis, acquired coagulopathy, significant bleeding or bruising) or to oral route of administration (unable to swallow tablets).
  12. Any known allergies to components contained in the investigational product or comparator or latex allergy (including polyethylene glycol [PEG] allergies) and/or history of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.
  13. Women who are pregnant (pregnancy tests will be performed at screening and prior to dosing), breastfeeding, or who plan to become pregnant during the study.
  14. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:

    1. Any history of:

      • GI
      • malabsorption
      • pancreatobiliary disorders
      • inflammatory bowel disease
      • irritable bowel disease
      • hiatal hernia
      • surgical resection
    2. History of diagnosis or treatment in past 5 years of:

      • esophageal or gastric motility disorder
      • gastroesophageal reflux disorder if any of the following is met: History of severe or uncontrolled gastroesophageal reflux disease (GERD) at any point during this period History of complicated GERD at any point during this period Was on treatment for 12 continuous weeks at any point during this period Has been with chronic or frequent GERD symptoms (e.g., more than twice per week) in the past year
      • peptic ulcer if any of the following is met: History of severe or uncontrolled peptic ulcer at any point during this period History of complicated peptic ulcer at any point during this period Was on treatment for 12 continuous weeks at any point during this period Has been with chronic or frequent peptic ulcer symptoms (e.g., more than twice per week) in the past year
      • cholecystectomy, if any of the following is met: Procedure was performed within 1 year of dosing, or The participant has ongoing/unresolved post-cholecystectomy digestive symptoms within 30 days prior to dosing
  15. Use of oral or parenterally administered antibiotics, proton pump inhibitors, H2 blockers, or antacids within 7 days prior to study drug administration or planned use from dosing through Day 31.
  16. Use of drugs known to affect gastrointestinal motility including glucagon-like peptide 1 (GLP-1) receptor agonists including tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic) within 30 days prior to drug administration. The participant may resume GLP-1 receptor agonists only if all solicited symptoms have completely resolved, with the earliest restart date being Day 9.
  17. Daily use (2 or more consecutive days) of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration through Day 8 (7 days post-vaccination). Low dose daily ASA ≤ 100 mg for cardio-protection is not exclusionary.
  18. Personal or familial history of hypercoagulable states to include personal past history of deep vein thrombosis (DVT).
  19. Personal history of myocarditis or pericarditis.
  20. Positive surface antigen (HBsAg), or virus (HCV) antibody at the screening visit. Confirmation of positive results with molecular testing is not required.
  21. History of drug, alcohol, or chemical abuse within 1 year of screening.
  22. Positive urine drug screen for drugs of abuse at screening, except in case of occasional marijuana use. Chronic marijuana use (as determined by the investigator's discretion) or a known history of marijuana abuse in the setting of a positive test is exclusionary. Concurrent or planned use of marijuana from dosing through Day 31 is prohibited. Positive urine drug screen (UDS) at screening due to prescribed stimulants will be reviewed on a case by case basis with the Medical Monitor's approval.
  23. Cancer, or treatment for cancer, within the past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma).
  24. History of any form of angioedema.
  25. History of GI bleeding including hematochezia (blood in stool) or melena (black stool) of unknown etiology or that has not been evaluated.
  26. Any history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia, including:

    1. Familial coagulopathy or personal history of bleeding disorder or thrombosis. A personal history of stroke, myocardial infarction, or similar condition may not be exclusionary if the participant is medically stable and not receiving a prohibited medication such as an anticoagulant or thrombolytic (low dose prophylactic aspirin is permitted)
    2. History of heparin-related thrombotic events, and/or receiving heparin treatments
    3. History of autoimmune or inflammatory disease
    4. Presence of any of the following conditions known to increase the risk of thrombosis within 6 months prior to screening:

      • Recent surgery other than fully healed cesarean delivery, excision/ of cutaneous lesions or other procedures that do not require general anesthetic and/or prolonged immobility
      • Immobility (confined to bed or wheelchair for 3 or more successive days)
      • Head trauma with loss of consciousness or documented brain injury
      • Receipt of anticoagulants for prophylaxis of thrombosis (low dose aspirin is permitted)
      • Recent infection including hospitalization for COVID-19 related illness.
  27. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results.
  28. Study team member or first-degree relative of any study team member (inclusive of sponsor and site personnel involved in the study).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
5,485 participants (estimated)

Study arms

  • Experimental
    VXA-CoV2-3.1 Safety Sentinel Cohort

    Participants previously immunized against COVID-19 infection will be randomized to receive VXA-CoV2-3.1 (XBB.1.5 vaccine) tablet oral vaccine.

    Biological: VXA-CoV2-3.1

  • Active comparator
    COMIRNATY® Safety Sentinel Cohort

    Participants previously immunized against COVID-19 infection will be randomized to receive COMIRNATY® (variant matched vaccine 2023-2024 formula) injectable COVID-19 vaccine.

    Biological: COMIRNATY®

  • Experimental
    VXA-CoV2-3.3

    If no dose-related toxicities are observed, and upon the recommendation of the Data and Safety Monitoring Board following review of Day 31 safety data in the initial safety cohorts (and possibly immunogenicity data), enrollment will continue with the remaining participants who will be randomized to receive a single dose of VXA-CoV2-3.3 (KP.2 vaccine).

    Biological: VXA-CoV2-3.3

  • Active comparator
    COMIRNATY®

    If no dose-related toxicities are observed, and upon the recommendation of the Data and Safety Monitoring Board following review of Day 31 safety data in the initial safety cohorts (and possibly immunogenicity data), enrollment will continue with the remaining participants who will be randomized to receive a single dose of 2024-2025 formula of COMIRNATY® mRNA COVID-19 injectable vaccine.

    Biological: COMIRNATY®

Interventions

  • BiologicalVXA-CoV2-3.1

    Tablets for oral use.

  • BiologicalCOMIRNATY®

    Intramuscular (IM) injection.

    Also known as: Pfizer-BioNTech mRNA Vaccine

  • BiologicalVXA-CoV2-3.3

    Tablets for oral use.

06

What researchers measure

Primary outcomes

  1. KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-vaccination

    Time frame: Up to approximately Day 14

  2. KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 at 12 Months Post-vaccination

    Time frame: Up to approximately 12 months

  3. XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccination

    Time frame: Up to approximately Day 7

  4. XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccination

    Time frame: Up to approximately Day 7

  5. XBB Sentinel Cohorts: Percentage of Participants who Experience Unsolicited Adverse Events (AEs) Through 30 Days Post-vaccination

    Time frame: Up to approximately Day 30

  6. XBB Sentinel Cohorts: Percentage of Participants who Experience Treatment-emergent Adverse Events (TEAEs) Through 12 Months Post-vaccination

    An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. An AE of special interest (AESI) is an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program. Medically attended AEs (MAAEs) are defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic. A serious TEAE (SAE) is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.

    Time frame: Up to approximately 12 months

  7. XBB Sentinel Cohorts: Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccination

    Time frame: Up to approximately Day 7

Secondary outcomes

  1. KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 Within 14 Days and 12 Months Post-vaccination in Participants with Specified Body Mass Index (BMI)

    Time frame: Up to approximately 12 months

  2. KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 within 0 and 180 Days Post-vaccination

    Time frame: Up to approximately 180 days

  3. KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 within 181 and 365 Days Post-vaccination

    Time frame: Up to approximately 365 days

  4. KP.2 Cohorts: Number of Participants with First Occurrence of Confirmed Asymptomatic PCR-Positive COVID-19 within 14 Days and 12 Months Post-vaccination from Self-administered at Home Tests

    Time frame: Up to approximately 12 months

  5. KP.2 Cohorts: Number of Participants with First Occurrence of Presumptive Asymptomatic PCR-Positive COVID-19 from Self-administered at Home Tests

    Time frame: Up to approximately 12 months

  6. KP.2 Cohorts: Number of Participants with First Occurrence of Severe PCR-Positive COVID-19 within 14 Days and 12 Months Post-vaccination

    Time frame: Up to approximately 12 months

  7. KP.2 Cohorts: Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccination

    Time frame: Up to approximately Day 7

  8. KP.2 Cohorts: Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccination

    Time frame: Up to approximately Day 7

  9. KP.2 Cohorts: Percentage of Participants who Experience Unsolicited AEs Through 30 Days Post-vaccination

    Time frame: Up to approximately Day 30

  10. KP.2 Cohorts: Percentage of Participants who Experience TEAEs Through 12 Months Post-vaccination

    An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. An AESI is an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program. MAAEs are defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic. An SAE is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.

    Time frame: Up to approximately 12 months

  11. KP.2 Cohorts: Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccination

    Time frame: Up to approximately Day 7

  12. KP.2 Cohorts: Geometric Mean titer (GMT) of SARS-CoV-2 Specific Serum Neutralizing Antibodies (nAb) Post-vaccination

    Time frame: Day 1 and Days 31, 91, 181, and 366

  13. KP.2 Cohorts: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific Serum nAb Post-vaccination

    Time frame: Day 1 and Days 31, 91, 181, and 366

  14. KP.2 Cohorts: Geometric Mean Concentration (GMC) of Serum Immunoglobulin G (IgG) Binding Antibody (bAb) Against Spike Protein (S) Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  15. KP.2 Cohorts: GMFR of Serum IgG Anti-S bAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  16. KP.2 Cohorts: GMC of Serum Immunoglobulin A (IgA) bAb Against S Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  17. KP.2 Cohorts: GMFR of Serum IgA Anti-S Specific bAb Post-vaccination

    Time frame: Day 1 and Days 31, 91, 181, and 366

  18. KP.2 Cohorts: GMT of SARS-CoV-2 Specific Saliva nAb Post-vaccination

    Time frame: Day 1 and Days 31, 91, 181, and 366

  19. KP.2 Cohorts: GMFR of SARS-CoV-2 Specific Saliva nAb Post-vaccination

    Time frame: Day 1 and Days 31, 91, 181, and 366

  20. KP.2 Cohorts: GMC of S-specific Saliva IgA bAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  21. KP.2 Cohorts: GMFR of S-specific Saliva IgA bAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  22. KP.2 Cohorts: GMT of SARS-CoV-2 specific Nasal Lining Fluid (NLF) nAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  23. KP.2 Cohorts: GMFR of SARS-CoV-2 specific NLF nAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  24. KP.2 Cohorts: GMC of S-specific NLF IgA bAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  25. KP.2 Cohorts: GMFR of S-specific NLF IgA bAb Post-vaccination

    Time frame: Days 1, 31, 91, 181, and 366

  26. KP.2 Cohorts: Percentage of Participants With 2, 3, and 4 Fold Rise in S-specific Serum IgG and IgA bAb, Serum nAb, Saliva IgA bAb, NLF IgA bAb, saliva nAb and NLF nAb Post-vaccination

    Time frame: Day 1 and Days 31, 91, 181, and 366

  27. KP.2 Cohorts: Concentration of Intracellular T Cell Cytokine and Cell Surface Marker

    Time frame: Days 1, 31, 91, 181, and 366

07

Study locations

145 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Core Clinical Trials - Central Alabama Research LLC
    Birmingham, Alabama 35209-8401, United States
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
  • Avacare - Lenzmeier Family Medicine
    Glendale, Arizona 85308, United States
  • Desert Clinical Research
    Mesa, Arizona 85213, United States
  • Velocity Clinical Research - MedPharmics - Phoenix
    Phoenix, Arizona 85020, United States
  • Foothills Research Center
    Phoenix, Arizona 85044, United States
  • Avacare (CCT) - Fiel Family & Sports Medicine
    Tempe, Arizona 85283, United States
  • Baptist Health Center for Clinical Research - Little Rock
    Little Rock, Arkansas 72205, United States
  • Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group
    Cerritos, California 90703, United States
  • Velocity Clinical Research - Chula Vista (eStudySite - Chula Vista)
    Chula Vista, California 91911, United States
  • Avacare - Benchmark Research - SOCAL-Colton
    Colton, California 92324, United States
  • Altasciences Los Angeles (Formerly WCCT Global)
    Cypress, California 90630, United States
  • Ark Clinical Research - Fountain Valley, CA
    Fountain Valley, California 92708, United States
  • Velocity Clinical Research - San Diego (eStudySite - La Mesa)
    La Mesa, California 91942, United States
  • Ark Clinical Research - Long Beach, CA
    Long Beach, California 90815, United States
  • Velocity Clinical Research (National Research Institute) - Panorama City
    Los Angeles, California 90057, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Avacare - Benchmark Research - Sacramento
    Sacramento, California 95864, United States
  • Velocity Clinical Research - Gardena
    Santa Ana, California 92704, United States
  • Elite Research Network (ERN) - Legacy Clinical Trials
    Colorado Springs, Colorado 80909, United States
  • Tekton Research - Fort Collins
    Fort Collins, Colorado 80528, United States
  • Avacare - Critical Care, Pulmonary and Sleep Associates
    Lakewood, Colorado 80228, United States
  • Tekton Research - Colorado - Longmont
    Longmont, Colorado 80501, United States
  • Paradigm Clinical Research - Wheat Ridge
    Wheat Ridge, Colorado 80033, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Chase Medical Research
    Waterbury, Connecticut 06708, United States
  • Velocity Clinical Research - Washington DC
    Washington D.C., District of Columbia 20016, United States
  • AMR - Miami (Clinical Research of South Florida)
    Coral Gables, Florida 33134, United States
  • Universal Axon Clinical Research
    Doral, Florida 33166, United States
  • Velocity Clinical Research - New Smyrna Beach
    Edgewater, Florida 32132, United States
  • Fleming Island Center For Clinical Research
    Fleming Island, Florida 32003, United States
  • AMR - Fort Myers - Clinical Physiology Associates
    Fort Myers, Florida 33912, United States
  • Velocity Clinical Research - Hallandale Beach (MD Clinical)
    Hallandale, Florida 33009, United States
  • ENCORE - Nature Coast Clinical Research Inverness
    Inverness, Florida 34452, United States
  • ENCORE - Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Headlands Research - JEM Research - Lake Worth
    Lake Worth, Florida 33462, United States
  • Accel Research Sites - Lakeland
    Lakeland, Florida 33803, United States
  • Accel Research Sites (ARS) - St. Petersburg - Largo
    Largo, Florida 33777, United States
  • Accel Research Sites - Maitland
    Maitland, Florida 32751, United States
  • K2 Medical Research - Maitland
    Maitland, Florida 32751, United States
  • SRA Trials LLC - Miami Clinical Trials at Suncoast Research Associates
    Miami, Florida 33173, United States
  • Atlas Clinical Research - Suncoast Clinical Research - Pasco County
    New Port Richey, Florida 34652, United States
  • Biscayne Clinical Research
    North Miami Beach, Florida 33169, United States
  • K2 Medical Research - South Orlando
    Orlando, Florida 32806, United States
  • Boca Raton Clinical Research (BRCR) Global - Weston
    Plantation, Florida 33322, United States
  • ENCORE - St. Johns Center for Clinical Research
    Saint Augustine, Florida 32086, United States
  • IMA Clinical Research - St. Petersburg
    St. Petersburg, Florida 33704, United States
  • hyperCORE - Centricity Research Columbus
    Columbus, Georgia 31904, United States
  • Javara Research - Privia Medical Group Georgia
    Fayetteville, Georgia 30214, United States
  • Privia Health - SouthCoast Health
    Fayetteville, Georgia 30214, United States
  • Avacare (CCT) - Lifeline Primary Care
    Lilburn, Georgia 30047, United States
  • hyperCORE - Centricity Research (IACT Health) - Rincon
    Rincon, Georgia 31326, United States
  • Velocity Clinical Research - Savannah
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research - Boise (Meridian)
    Meridian, Idaho 83642, United States
  • IMA Clinical Research - Chicago
    Chicago, Illinois 60602, United States
  • Accellacare - Duly Health and Care
    Lombard, Illinois 60148, United States
  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research)
    Valparaiso, Indiana 46383, United States
  • Accellacare - McFarland Clinic
    Ames, Iowa 50010, United States
  • Velocity (Meridian) Clinical Research - Sioux City
    Sioux City, Iowa 51106, United States
  • AMR - El Dorado - Heartland Research Associates
    El Dorado, Kansas 67042, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • AMR - Newton (Heartland Research Associates)
    Newton, Kansas 67114, United States
  • AMR - Wichita West - Heartland Research Associates
    Wichita, Kansas 67205, United States
  • AMR - Wichita East - Heartland Research Associates
    Wichita, Kansas 67207, United States
  • AMR - Lexington (Central Kentucky Research Associates)
    Lexington, Kentucky 40509, United States
  • Velocity (Meridian) Clinical Research - Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Avacare - Benchmark Research - New Orleans-North Shore
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research - MedPharmics - Covington
    Covington, Louisiana 70433, United States
  • Boca Raton Clinical Research (BRCR) Global USA - New Orleans
    Gretna, Louisiana 70053, United States
  • Velocity Clinical Research - MedPharmics - Lafayette
    Lafayette, Louisiana 70508, United States
  • Avacare - Benchmark Research - Metairie
    Metairie, Louisiana 70006, United States
  • AMR - New Orleans - Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • Javara Research - Privia Medical Group Mid-Atlantic - Annapolis
    Annapolis, Maryland 21401, United States
  • Pharmaron
    Baltimore, Maryland 21201, United States
  • Avacare (CCT) - Advanced Primary and Geriatric Care
    Rockville, Maryland 20850, United States
  • Velocity (Meridian) Clinical Research - Rockville
    Rockville, Maryland 20854, United States
  • Javara Research - Mankato Clinic
    Mankato, Minnesota 56001, United States
  • Velocity Clinical Research - MedPharmics - Gulfport
    Gulfport, Mississippi 39503, United States
  • Avacare (CCT) - Clay Platte Family Medicine Clinic
    Kansas City, Missouri 64151, United States
  • Avacare (CCT) - Skyline Medical Center
    Elkhorn, Nebraska 68022, United States
  • Velocity (Meridian) Clinical Research - Grand Island
    Grand Island, Nebraska 68803, United States
  • Be Well Clinical Studies - Nebraska
    Lincoln, Nebraska 68516, United States
  • Velocity (Meridian) Clinical Research - Omaha
    Omaha, Nebraska 68134, United States
  • hyperCORE - ActivMed Practices and Research - Portsmouth
    Portsmouth, New Hampshire 03801, United States
  • DM Clinical Research - Jersey City
    Jersey City, New Jersey 07306, United States
  • Velocity Clinical Research - Alburquerque
    Albuquerque, New Mexico 87107, United States
  • AXCES Research & Health - Santa Fe
    Santa Fe, New Mexico 87505, United States
  • IMA Clinical Research - Albany, Suite 202
    Albany, New York 12205, United States
  • Velocity Clinical Research - Syracuse
    East Syracuse, New York 13057, United States
  • IMA Clinical Research - Manhattan
    New York, New York 10036, United States
  • Atlas Clinical Research - Rochester Clinical Research
    Rochester, New York 14609, United States
  • Cary Medical Group
    Cary, North Carolina 27518, United States
  • Velocity Clinical Research - Durham
    Durham, North Carolina 27701, United States
  • Accellacare - Hickory
    Hickory, North Carolina 28601, United States
  • Accellacare - Raleigh
    Raleigh, North Carolina 27609, United States
  • Accellacare - Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • Accellacare - Salisbury
    Salisbury, North Carolina 28144, United States
  • Accellacare - Piedmont Healthcare
    Statesville, North Carolina 28625, United States

Showing the first 100 of 145 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2027, 31 months after the start.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 31 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Oct 8, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and responsible party
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06672055
Lead sponsor
Vaxart
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Oct 8, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

James Cummings, MD
study director · Vaxart, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion